\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ revealed\\ decreased\\ left\\ visual\\ acuity\\ with\\ a\\ relative\\ afferent\\ left\\ pupillary\\ defecit\\.\\ \\ the\\ remainder\\ of\\ the\\ exam\\ was\\ unremarkable\\.\ \(0\)\
\-\ patient\\ was\\ placed\\ on\\ oral\\ corticosteroids\\.\ \(0\)\
\-\ follow\\-up\\ mri\\ of\\ the\\ orbits\\ demonstrated\\ significant\\ decrease\\ enhancement\\ of\\ the\\ left\\ optic\\ nerve\\ dura\\ and\\ decrease\\ in\\ size\\ of\\ the\\ left\\ optic\\ nerve\\.\ \(0\)\
\-\ mri\\ of\\ the\\ orbits\\ reveals\\ enlargement\\ of\\ the\\ left\\ optic\\ nerve\\ extending\\ from\\ the\\ globe\\ to\\ the\\ optic\\ chiasm\\ with\\ diffuse\\ abnormal\\ thickening\\ and\\ enhancement\\ of\\ the\\ optic\\ nerve\\ dura\\ creating\\ a\\ tram\\-track\\ appearance\\.\\ \\ the\\ remainder\\ of\\ the\\ left\\ orbit\\ is\\ normal\\ in\\ appearance\\.\\ \\ the\\ lacrimal\\ glands\\ are\\ normal\\ bilaterally\\.\\ \\ the\\ brain\\ is\\ normal\\ in\\ appearance\\ with\\ no\\ abnormal\\ parenchymal\\ or\\ leptomeningeal\\ enhancement\\.\ \(0\)\
\-\ orbital\\ sarcoidosis\ \(0\)\
\-\ 1\\.\\ \\ optic\\ nerve\\ meningioma\ \(0\)\
\-\ 2\\.\\ \\ optic\\ nerve\\ sarcoidosis\ \(0\)\
\-\ 3\\.\\ \\ optic\\ nerve\\ glioma\ \(0\)\
\-\ 4\\.\\ \\ orbital\\ pseudotumor\ \(0\)\
\-\ 5\\.\\ \\ lymphoma\ \(0\)\
\-\ 6\\.\\ \\ tuberculosis\ \(0\)\
\-\ 36\\-year\\-old\\ female\\ with\\ gradual\\ loss\\ of\\ vision\\ in\\ her\\ left\\ eye\\,\\ claiming\\ that\\ her\\ vision\\ has\\ become\\ darker\\ and\\ darker\\.\\ \\ the\\ patient\\ also\\ complains\\ of\\ dryness\\ in\\ her\\ left\\ eye\\ and\\ feeling\\ of\\ pressure\\ behind\\ her\\ left\\ eye\\.\\ \\ patient\\ is\\ otherwise\\ healthy\\ with\\ no\\ significant\\ past\\ medical\\ history\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.477693509329113\ \(0\)\
\-\ nerve\\:\\ 0\\.34640041017509243\ \(0\)\
\-\ left\\:\\ 0\\.21296213974203904\ \(0\)\
\-\ darker\\:\\ 0\\.21200345782010405\ \(0\)\
\-\ the\\:\\ 0\\.20761725110628534\ \(0\)\
\-\ her\\:\\ 0\\.17334526550551146\ \(0\)\
\-\ eye\\:\\ 0\\.16647627512995017\ \(0\)\
\-\ orbits\\:\\ 0\\.15682785309520694\ \(0\)\
\-\ dura\\:\\ 0\\.15090283292815054\ \(0\)\
\-\ of\\:\\ 0\\.14932210137593926\ \(0\)\
\-\ appearance\\:\\ 0\\.12545530295847274\ \(0\)\
\-\ remainder\\:\\ 0\\.12208609279913933\ \(0\)\
\-\ orbital\\:\\ 0\\.12168738652228582\ \(0\)\
\-\ vision\\:\\ 0\\.12015487723126303\ \(0\)\
\-\ enhancement\\:\\ 0\\.11977862141629471\ \(0\)\
\-\ decrease\\:\\ 0\\.11924388915084404\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.11751830474594413\ \(0\)\
\-\ defecit\\:\\ 0\\.1109322937348211\ \(0\)\
\-\ claiming\\:\\ 0\\.1109322937348211\ \(0\)\
\-\ dryness\\:\\ 0\\.10600172891005202\ \(0\)\
\-\ afferent\\:\\ 0\\.09407458125345501\ \(0\)\
\-\ pupillary\\:\\ 0\\.08817067556397919\ \(0\)\
\-\ in\\:\\ 0\\.08628079360587529\ \(0\)\
\-\ normal\\:\\ 0\\.08496575234720392\ \(0\)\
\-\ abnormal\\:\\ 0\\.08334904825973001\ \(0\)\
\-\ creating\\:\\ 0\\.08233893785545451\ \(0\)\
\-\ lacrimal\\:\\ 0\\.08233893785545451\ \(0\)\
\-\ significant\\:\\ 0\\.08010149292482674\ \(0\)\
\-\ gradual\\:\\ 0\\.07841392654760347\ \(0\)\
\-\ acuity\\:\\ 0\\.07721686877208891\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.07512712340316291\ \(0\)\
\-\ chiasm\\:\\ 0\\.0736239444342349\ \(0\)\
\-\ glands\\:\\ 0\\.0736239444342349\ \(0\)\
\-\ feeling\\:\\ 0\\.0736239444342349\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.07334438570617081\ \(0\)\
\-\ globe\\:\\ 0\\.07228630394731983\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.07203556786630913\ \(0\)\
\-\ mri\\:\\ 0\\.07121331454386877\ \(0\)\
\-\ exam\\:\\ 0\\.06983836175580452\ \(0\)\
\-\ with\\:\\ 0\\.06791423695269541\ \(0\)\
\-\ patient\\:\\ 0\\.06768441759456785\ \(0\)\
\-\ behind\\:\\ 0\\.06685933268403473\ \(0\)\
\-\ orbit\\:\\ 0\\.06424352042167868\ \(0\)\
\-\ parenchymal\\:\\ 0\\.06231309729151497\ \(0\)\
\-\ become\\:\\ 0\\.06155621406623737\ \(0\)\
\-\ relative\\:\\ 0\\.061451833433074934\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.061043046399569666\ \(0\)\
\-\ complains\\:\\ 0\\.06035915629072282\ \(0\)\
\-\ visual\\:\\ 0\\.05918289800316048\ \(0\)\
\-\ glioma\\:\\ 0\\.058926882881867704\ \(0\)\
\-\ healthy\\:\\ 0\\.058842728434594815\ \(0\)\
\-\ and\\:\\ 0\\.05733503412855511\ \(0\)\
\-\ is\\:\\ 0\\.05698954364129535\ \(0\)\
\-\ oral\\:\\ 0\\.05555592529015427\ \(0\)\
\-\ placed\\:\\ 0\\.05405274632122625\ \(0\)\
\-\ enlargement\\:\\ 0\\.05317988606748727\ \(0\)\
\-\ pressure\\:\\ 0\\.052816866002190606\ \(0\)\
\-\ reveals\\:\\ 0\\.052765879474250064\ \(0\)\
\-\ meningioma\\:\\ 0\\.05197789411901039\ \(0\)\
\-\ otherwise\\:\\ 0\\.049446984112109856\ \(0\)\
\-\ was\\:\\ 0\\.048349893366568385\ \(0\)\
\-\ thickening\\:\\ 0\\.047191239483867206\ \(0\)\
\-\ extending\\:\\ 0\\.04703144389799297\ \(0\)\
\-\ size\\:\\ 0\\.04696810901993075\ \(0\)\
\-\ unremarkable\\:\\ 0\\.046503328786754665\ \(0\)\
\-\ bilaterally\\:\\ 0\\.04626252350996989\ \(0\)\
\-\ revealed\\:\\ 0\\.04548330736914269\ \(0\)\
\-\ past\\:\\ 0\\.04515239527381192\ \(0\)\
\-\ no\\:\\ 0\\.045114457700126225\ \(0\)\
\-\ medical\\:\\ 0\\.0440852488338861\ \(0\)\
\-\ diffuse\\:\\ 0\\.043501443809356714\ \(0\)\
\-\ brain\\:\\ 0\\.0432429549266178\ \(0\)\
\-\ decreased\\:\\ 0\\.04296709578280945\ \(0\)\
\-\ demonstrated\\:\\ 0\\.042630845720836565\ \(0\)\
\-\ loss\\:\\ 0\\.04226067465909813\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04131210518022129\ \(0\)\
\-\ physical\\:\\ 0\\.037612162618455125\ \(0\)\
\-\ female\\:\\ 0\\.03347258365092293\ \(0\)\
\-\ also\\:\\ 0\\.032628060400789964\ \(0\)\
\-\ has\\:\\ 0\\.031684641473175665\ \(0\)\
\-\ that\\:\\ 0\\.0301025028225466\ \(0\)\
\-\ from\\:\\ 0\\.027549472478488688\ \(0\)\
\-\ history\\:\\ 0\\.02650205668742861\ \(0\)\
\-\ are\\:\\ 0\\.026321469731705783\ \(0\)\
\-\ or\\:\\ 0\\.02413140479395817\ \(0\)\
\-\ on\\:\\ 0\\.020949903704141966\ \(0\)\
\-\ to\\:\\ 0\\.01734151361527393\ \(0\)\
